Titan Pharma (TTNP) – Company Press Releases
-
Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria
-
Titan Pharmaceuticals Announces Reverse Stock Split and Ratio
-
Titan Pharmaceuticals Announces Appointment of Dato' Seow Gim Shen and Brynner Chaim to the Company's Board of Directors
-
Titan Pharmaceuticals Announces Appointment of Dato' Seow Gim Shen and Brynner Chaim to the Company's Board of Directors
-
Titan Pharmaceuticals Announces $9.5 Million Private Placement of Convertible Preferred Stock
-
Titan Pharmaceuticals Announces Sale of Certain ProNeura Assets
-
Titan Pharmaceuticals Provides Shareholder Update
-
Titan Pharmaceuticals Provides Shareholder Update
-
UPDATE -- Titan Pharmaceuticals Inc. Announces Licensing Agreement with Ocular Therapeutix Inc.
-
UPDATE -- Titan Pharmaceuticals Inc. Announces Licensing Agreement with Ocular Therapeutix Inc.
-
Titan Pharmaceuticals Inc. Announces Licensing Agreement with Ocular Therapeutix Inc.
-
Titan Pharmaceuticals Inc. Announces Licensing Agreement with Ocular Therapeutix Inc.
-
Titan Pharmaceuticals Announces Board Expansion and Management Changes
-
Activist Investing Nominates Slate of Highly Qualified Director Candidates for Election to the Board of Directors of Titan Pharmaceuticals at Upcoming Special Meeting of Stockholders
-
Activist Investing Nominates Slate of Highly Qualified Director Candidates for Election to the Board of Directors of Titan Pharmaceuticals at Upcoming Special Meeting of Stockholders
-
Titan Pharmaceuticals Announces FDA Clearance of IND Application for Nalmefene Implant
-
Activist Investing Discloses 9.9% Ownership Interest in Titan Pharmaceuticals, Inc.
-
Activist Investing Discloses 9.9% Ownership Interest in Titan Pharmaceuticals, Inc.
-
Activist Investing Announces 5.6% Ownership Interest in Titan Pharmaceuticals, Inc.
-
Activist Investing Announces 5.6% Ownership Interest in Titan Pharmaceuticals, Inc.
-
Titan Pharmaceuticals Announces Pricing of $5.5 Million Registered Direct and PIPE Offering Priced At-The-Market
-
Titan Pharmaceuticals to Explore Strategic Alternatives
-
Sustained Anti-Pruritic Effect Of Titan's TP-2021 Implant Reported Today At Neuroscience 2021
-
Titan Announces Upcoming TP-2021 Implant Data Presentation at Neuroscience 2021
-
Titan Pharmaceuticals Receives Funding to Develop Combination HIV Therapeutic and Contraceptive Implant for Women in Developing Countries
-
Titan Pharmaceuticals and MUSC FRD Enter Into Research and Option License Agreement
-
Titan Announces Positive Results from the First Studies of TP-2021 Implant in an Established Animal Model of Chronic Pruritus
-
Titan Pharmaceuticals Announces Filing Of 2020 Annual Report On Form 10-K
-
Positive Early Study Results Help Pave Wave for Titan Pharmaceuticals to Move Forward with its JT-09 ProNeura® Development Program
-
Titan Pharmaceuticals Announces Pricing of $9.7 Million Registered Direct Offering
-
Titan Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements
-
Titan Pharmaceuticals Announces Reverse Stock Split
-
Titan Pharmaceuticals Reports Third Quarter 2020 Financial Results
-
Titan Pharmaceuticals Completes Debt Settlement With Molteni And Horizon & Acquisiton Of JT Pharma's Kappa Opioid Agonist Peptide, JT-09
-
Titan Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering
-
Titan Pharmaceuticals Enters Into Definitive Agreement To Acquire JT Pharma's Kappa Opioid Agonist Peptide, JT-09
-
Titan Pharmaceuticals Announces Debt Settlement Agreement with Molteni and Horizon
-
Titan Pharmaceuticals Provides a Strategic & Corporate Update
-
Titan Pharmaceuticals Announces Pricing of $2.7 Million Registered Direct Offering
-
Titan Pharmaceuticals' Stockholders Approve Proposal To Amend Its Certificate Of Incorporation
-
Titan's Probuphine® Commercialization Partner, Molteni, Enters Into Exclusive European Distribution Agreement With Accord Healthcare
-
Titan Pharmaceuticals Provides Update To Stockholders On Proposal To Amend Its Certificate Of Incorporation
-
Titan Pharmaceuticals Reports Second Quarter 2020 Financial Results
-
Titan Pharmaceuticals To Report Second Quarter 2020 Financial Results On August 14, 2020
-
Titan Pharmaceuticals Urges Stockholders to Vote "FOR" Proposal to Amend Its Certificate of Incorporation
-
Titan Pharmaceuticals And Indegene Enter Into Probuphine® Co-Promotion Partnership
-
Titan Pharmaceuticals Launches Virtual REMS Training For Probuphine Health Care Providers
-
Titan Pharmaceuticals Reports First Quarter 2020 Financial Results
-
Titan Pharmaceuticals To Report First Quarter 2020 Financial Results On May 15, 2020
-
Titan Pharmaceuticals Reports Fourth Quarter And Full Year 2019 Financial Results
Back to TTNP Stock Lookup
